Table 3 Evidence from clinical trials of the efficacy and safety of parenteral anticoagulants in the treatment of VTE

Inpatient VTE treatment

   Enoxaparin

[52]

900

1.5 mg/kg once daily

DVT with/without PE

IV UFH

4.4 vs 4.1*

1.7 vs 2.1*

1.0 mg/kg bid

2.9 vs 4.1*

1.3 vs 2.1*

   Dalteparin

[53]

204

200 IU/kg once daily

DVT

IV UFH

5.0 vs 2.9

0 vs 0

[54]

253

200 IU/kg once daily

DVT

IV UFH

3.6 vs 1.7

0 vs 1.5

   Tinzaparin

THESEE [55]

612

175 IU/kg once daily

PE

IV UFH

1.6 vs 1.9*

2.0 vs 2.6*

   Fondaparinux

MATISSE [59]

2,213

5 mg (body weight <50 kg), 7.5 mg (50-100 kg), or 10 mg (>100 kg)

PE

IV UFH

3.8 vs 5.0*

2.0 vs 2.4*

[60]

2,205

5 mg (body weight <50 kg), 7.5 mg (50-100 kg), or 10 mg (>100 kg)

DVT

Enoxaparin 1.0 mg/kg bid

3.9 vs 4.1*

2.6 vs 2.4*

Outpatient treatment

   Enoxaparin

[56]

500

1.0 mg/kg bid

DVT

IV UFH (inpatient)

5.3 vs 6.7

2.0 vs 1.2

[61]

298

1.5 mg/kg once daily

DVT

IV UFH (inpatient)

2.7 vs 8.8 (p = 0.026)

0 vs 2.0

   Tinzaparin

[57]

505

175 IU/kg once daily

DVT and/or PE

Dalteparin 200 IU/kg once daily

3.9 vs 3.6

2.0 vs 0.8